Barrington Remains a Buy on Lemaitre Vascular (LMAT)
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 7.7% and a 50.0% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, ATI Physical Therapy, and US Physical Therapy.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lemaitre Vascular with a $47.50 average price target.See the top stocks recommended by analysts >> Based on Lemaitre Vasculars latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $39.56 million and net profit of $6.04 million. In comparison, last year the company earned revenue of $35.88 million and had a net profit of $5.93 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA. Read More on LMAT:
- Deutsche Bank AG (DB) Gets a Hold Rating from RBC Capital
- Acutus Medical (AFIB) Gets a Buy Rating from BTIG
- The First of Long Island Corporation Announces Second Quarter Cash Dividend of $.20 Per Share
- Lakeland Bancorp Announces Date for Second Quarter Earnings and Conference Call
- Stellantis to Host Startup Awards July 13 to Introduce Key Technology Partnerships
Paid Post: Content produced by TipRanks. The Globe and Mail was not involved, and material was not reviewed prior to publication.